The ORR was similar in CLL patients who had been exposed and become resistant to covalent BTKi, had developed intolerance to covalent BTKi, had acquired a Cys481 mutation in the BTK gene, or had a BTK wild-type disease [57]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.